Drawing for BELLA LOVES ME.

USPTO serial 90639094

BELLA LOVES ME.

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CHOSID, ROBIN S
Law office
TMO LAW OFFICE 130 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with BELLA LOVES ME.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kimberly S. Grimsley

Kimberly S. Grimsley OLIVER & GRIMSLEY, LLC502 WASHINGTON AVENUESUITE 605TOWSON, MD 21204

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic kits comprised of medical diagnostic assays for use in disease detection, screening, treating and monitoring, namely, monitoring COVID-19 and other infectious diseases; Respiratory rapid tests, namely, assays for use in performing respiratory rapid tests related to COVID-19 and other infectious diseases; Screening tests and devices to detect COVID-19 and other infectious diseases in a patientACTIVE—
009Downloadable computer application software for mobile phones, namely, software for covid-19 and other infectious disease identification; Downloadable computer application software for computers, namely, software for covid-19 and other infectious disease identification; Downloadable mobile applications for health screenings relating to COVID-19 and other infectious disease; Downloadable mobile applications for tracking and reporting health conditions and symptomsACTIVE—
042Providing temporary use of online non-downloadable software for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; Scientific apparatus and instruments, namely, COVID-19 rapid tests for withdrawing and testing respiratory droplets for clinical, medical, research, and scientific purposes and parts and fittings thereof; Material testing apparatus and instruments, for identifying and testing pathogens and biomarkers in respiratory droplets for clinical, medical, research, and scientific purposes related to COVID-19 and other infectious diseases; Apparatus for transmission of communication; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical, medical, research, and scientific purposes, namely, for COVID-19 and other infectious diseases; Providing temporary use of online non-downloadable software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Providing temporary use of web-based software applications for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Software as a service (SAAS) services featuring software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptomsACTIVE—
044Healthcare services; Medical and healthcare information, consultancy and advisory services relating to infections, viruses, SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Providing a web site featuring medical information; Health care services, namely, disease management programs; Telehealth services, namely, providing telemedicine and services in conjunction with providing medical and healthcare services; Information collection and management services in the field of public health, namely, collecting, verifying, tracing, tracking, storing, monitoring, and notifying physical sites visited by persons infected with contagious disease for the purpose of slowing or stopping the spread of the disease under the guidance of state and local public health departments; Information collection and management services in the field of public health, namely, collecting, verifying, tracing, tracking, storing, monitoring, and notifying contacts of persons infected with contagious disease for the purpose of slowing or stopping the spread of the disease under the guidance of state and local public health departments; Mobile healthcare services in the field of Covid and other infectious disease testing, health assessments, intravenous infusion therapy, facilitating appointmentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Aug 1, 2022MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 30, 2022MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 30, 2022ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 8, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 8, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 8, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 1, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 30, 2021DOCKASSIGNED TO EXAMINER—
Jul 19, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 15, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance